IQV IQVIA Holdings Inc.
USHealthcareAs of 2026-07-10 16:00
Why IQV matters now
IQVIA Holdings Inc. (IQV) is a US stock in Healthcare. The latest InvestLog snapshot shows $207.85 with -0.54% on the session and $34.69B in market capitalization; recent performance reads 1-month -3.12% and YTD -25.57%.
The latest financial table shown here is Q1 2026, with revenue of $4.15B, net income of $274.0M, and EPS of $1.61. Investors can compare that operating picture with valuation signals such as P/E 20.88 and FCF yield 9.1%.
The latest indexable market news headline is "Here's Why IQVIA Holdings (IQV) is a Strong Value Stock" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $215.00; recent insider activity includes DANHAKL JOHN G filing A-Award; recent congressional disclosure data includes Kevin Hern Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
20.88
PEG
—
P/B
4.54
P/S
1.68
EV/EBITDA
11.97
DCF Value
$279.85
FCF Yield
9.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
26.1%
Operating Margin
13.9%
Net Margin
8.3%
ROE
22.5%
ROA
4.7%
ROIC
8.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.15B | $274.0M | $1.61 |
| Q4 2025 | $4.36B | $514.0M | $2.99 |
| FY 2025 | $16.31B | $1.36B | $7.84 |
| Q3 2025 | $4.10B | $331.0M | $1.93 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$219.44
Target (Median)
$215.00
Target Range
$185.00 - $250.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.22
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.